Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B16F10 cell vaccine is an experimental whole-cell cancer vaccine derived from the B16F10 murine melanoma cell line. It is typically prepared by inactivating the cells, such as through repeated freeze-thaw cycles or irradiation, to release a broad spectrum of tumor-associated antigens (TAAs) while rendering the cells non-tumorigenic. The vaccine is designed to stimulate the host's immune system, specifically inducing natural killer (NK) cell cytotoxicity and the production of anti-tumor cytokines like interferon-gamma (IFN-γ). Research indicates that Mucin 1 (MUC1) is a critical immunogenic component of this vaccine, and its presence is essential for the induction of effective anti-melanoma immune responses in mouse models. It is primarily used as a research tool to study tumor immunology and evaluate candidate target antigens for melanoma vaccine development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on B16F10 cell vaccine.